Several tools could lower prices directly—and serve as an indirect incentive to get Congress to act.
Big Pharma
Posted inCoronavirus
Pfizer’s Bottom Line
As the pharmaceutical company makes a pitch for booster shots, epidemiologists question its motives and worry boosters might stymie global vaccine efforts.
Posted inPolitics
Biden Will Nominate Industry Ally for Patent Office
It’s an about-face from the president’s previous commitment to waive patent protections for COVID-19 vaccines.
Posted inMoney, Politics, and Power
Pharma Companies Spend Billions More on Stock Buybacks Than Developing Drugs
House Oversight Committee report combats industry claims that lower drug prices would stifle innovation.
Posted inTAP
Wyden Sticks It to Biden (for Big Tech)
Today on TAP: Sen. Ron Wyden and the China bill
Posted inHealth and Social Policy
The Post-COVID Health Care System Is Out of Control
After gouging Americans for record pandemic profits, the health care industry sets its sights on even more.
Posted inMoney, Politics, and Power
Clyburn’s Corporate Foundation
How to earn goodwill with one of the most powerful members of Congress
Posted inCabinet Watch
Chris Coons Working to Install Business-Friendly Candidate for Key Patent Position
The Delaware senator wants a say in the next director of the U.S. Patent and Trademark Office, and claims to have a deal with the White House.
Posted inHealth and Social Policy
The Dangers of Ducking the Health Care Fight
Each day that policymakers decide not to take on health interests is a day that those interests get bigger and tougher to dislodge.
